Research programme: CNS disorder therapeutics - NB Health Laboratory

Drug Profile

Research programme: CNS disorder therapeutics - NB Health Laboratory

Alternative Names: P 005

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NB Health Laboratory
  • Class Small molecules
  • Mechanism of Action Casein kinase Idelta inhibitors; Casein kinase Iepsilon inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Alzheimer's disease; Insomnia; Somnambulism

Most Recent Events

  • 13 Sep 2016 Early research in Somnambulism in Japan (unspecified route) (NB Health laboratory website, September 2016)
  • 13 Sep 2016 NB Health laboratories has patent protection for P 005 in Japan, Europe and USA (NB Health Laboratories pipeline, September 2016)
  • 13 Sep 2016 Research programme: CNS disorder therapeutics - NB Health Laboratory is available for licensing as of 13 Sep 2016. http://www.nbhl.co.jp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top